Kyverna Therapeutics, Inc. Common Stock (KYTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kyverna Therapeutics, Inc. Common Stock (KYTX) has a cash flow conversion efficiency ratio of -0.213x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-41.60 Million) by net assets ($195.58 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see KYTX market cap for the company's overall valuation and market capitalisation.
Kyverna Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Kyverna Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Kyverna Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kyverna Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency. See Kyverna Therapeutics, Inc. Common Stock debt service capacity to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Salmones Camanchaca S.A
SN:SALMOCAM
|
-0.019x |
|
Shenyang Chemical Industry Co Ltd
SHE:000698
|
0.135x |
|
Codere Online US Corp
NASDAQ:CDRO
|
0.135x |
|
Multiconsult AS
OL:MULTI
|
0.212x |
|
PureTech Health PLC
NASDAQ:PRTC
|
-0.126x |
|
Posiflex Technology Inc
TW:8114
|
-0.061x |
|
Tangel Publishing
SHE:300148
|
-0.009x |
|
Hangzhou Zhongya Machinery Co Ltd
SHE:300512
|
0.026x |
Annual Cash Flow Conversion Efficiency for Kyverna Therapeutics, Inc. Common Stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of Kyverna Therapeutics, Inc. Common Stock from 2021 to 2025. View Kyverna Therapeutics, Inc. Common Stock stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $232.28 Million | $-153.71 Million | -0.662x | -54.41% |
| 2024-12-31 | $266.59 Million | $-114.25 Million | -0.429x | +59.79% |
| 2023-12-31 | $49.18 Million | $-52.41 Million | -1.066x | -37.75% |
| 2022-12-31 | $46.68 Million | $-36.11 Million | -0.774x | -261.52% |
| 2021-12-31 | $-46.25 Million | $-22.16 Million | 0.479x | -- |
About Kyverna Therapeutics, Inc. Common Stock
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product ca… Read more